Background: Skin disorders frequently seen among primary school children are common causes of morbidity. Determining the risk factors of skin diseases, will enhance a better understanding of skin health and prevent skin diseases in school children.
Aim: To determine the common risk factors of skin diseases among primary school children in Umuahia South Local Government Area of Abia State.
Methods: A descriptive cross-sectional study carried out over a 4-month period among pupils of public and private primary schools. Diagnosis of skin diseases was based on clinical findings as well as laboratory investigations where indicated. A pre-tested, self-administered, close ended questionnaire was used to ascertain the risk factors of skin diseases.
Results: Eight hundred and forty-seven (847) and seven hundred and thirteen (713) subjects were recruited from public and private schools respectively. Fifty-six percent of the subjects were males. The mean age of the study participants was 8.74 ± 2.08 years. The overall prevalence of skin diseases was 40.2%. Using a multivariate logistic regression, gender, number of people per room, frequency of bathing per week and source of water were found to be significant risk factors for skin diseases.
Conclusion: Socio-demographic factors and living conditions are significant risk factors of skin diseases. Standard hygienic practices by school children and their parents/ caregivers will help to reduce the high prevalence of skin diseases in our environment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Usability and Usefulness of a Symptom Management Coaching System for Patients With Cancer Treated With Immune Checkpoint Inhibitors: Comparative Mixed Methods Study.
JMIR Form Res
January 2025
Department of Medical Informatics, Amsterdam UMC - University of Amsterdam, Amsterdam, Netherlands.
Background: The prognosis for patients with several types of cancer has substantially improved following the introduction of immune checkpoint inhibitors, a novel type of immunotherapy. However, patients may experience symptoms both from the cancer itself and from the medication. A prototype of the eHealth tool Cancer Patients Better Life Experience (CAPABLE) was developed to facilitate symptom management, aimed at patients with melanoma and renal cell carcinoma treated with immunotherapy.
View Article and Find Full Text PDFImpact of the COVID-19 Pandemic on Breast Cancer Patient Care: Results From a Tertiary Care Center in Lebanon.
JCO Glob Oncol
January 2025
Department of Surgery, American University of Beirut, Beirut, Lebanon.
Purpose: We aimed to evaluate the impact of COVID-19 on breast cancer care in terms of the stage at presentation, treatment delays, and follow-up in a tertiary care center in Lebanon.
Materials And Methods: This retrospective study compared patients with breast cancer who presented to a tertiary care center in Lebanon before (September 2019-December 2019) and during (September 2020-December 2020) the COVID-19 pandemic. We extracted data from the electronic medical records of patients with breast cancer who had their initial presentation, were under treatment, or were on follow-up during our period of interest.
Post-traumatic growth experience of breast cancer patients: A qualitative systematic review and meta-synthesis.
PLoS One
January 2025
Guang'an Hospital of Traditional Chinese Medicine, Guang'an, Sichuan Province, China.
Objectives: This study aimed to systematically incorporate the post-traumatic growth experience of breast cancer patients and furnish insights for the formulation of targeted psychological care measures.
Methods: The search period we were ranged from establishing the database to February 2024. We systematically searched four Chinese databases and seven English databases.
Orismilast, a PDE4B/D inhibitor, in moderate-to-severe atopic dermatitis: Efficacy and safety from a multicenter, randomized, placebo-controlled, phase 2b dose-ranging study (ADESOS).
Br J Dermatol
January 2025
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, characterized by eczematous skin lesions and pruritus. There is an unmet need for effective first-line systemic therapies with good safety profiles, particularly oral medications. Orismilast is a novel first-in-class oral phosphodiesterase-4 (PDE4) B/D inhibitor under investigation for the treatment of moderate-to-severe AD.
View Article and Find Full Text PDFCeftobiprole: A therapeutic update.
Am J Health Syst Pharm
January 2025
Pharmacotherapy Department, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, WA, USA.
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!